Kassirer Asset Management Corp reduced its stake in PAREXEL International Co. (NASDAQ:PRXL) by 25.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 52,400 shares of the medical research company’s stock after selling 17,600 shares during the period. PAREXEL International accounts for approximately 4.4% of Kassirer Asset Management Corp’s investment portfolio, making the stock its 8th biggest position. Kassirer Asset Management Corp’s holdings in PAREXEL International were worth $4,615,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. World Asset Management Inc boosted its position in shares of PAREXEL International by 0.3% in the second quarter. World Asset Management Inc now owns 3,212 shares of the medical research company’s stock valued at $279,000 after acquiring an additional 9 shares during the period. 1st Global Advisors Inc. boosted its position in shares of PAREXEL International by 0.4% in the second quarter. 1st Global Advisors Inc. now owns 5,391 shares of the medical research company’s stock valued at $469,000 after acquiring an additional 21 shares during the period. Amalgamated Bank boosted its position in shares of PAREXEL International by 0.6% in the second quarter. Amalgamated Bank now owns 7,259 shares of the medical research company’s stock valued at $631,000 after acquiring an additional 42 shares during the period. Public Employees Retirement System of Ohio boosted its position in shares of PAREXEL International by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after acquiring an additional 73 shares during the period. Finally, Texas Permanent School Fund boosted its position in shares of PAREXEL International by 0.5% in the second quarter. Texas Permanent School Fund now owns 37,062 shares of the medical research company’s stock valued at $3,221,000 after acquiring an additional 169 shares during the period. Hedge funds and other institutional investors own 87.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “PAREXEL International Co. (PRXL) is Kassirer Asset Management Corp’s 8th Largest Position” was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/parexel-international-co-prxl-is-kassirer-asset-management-corps-8th-largest-position/1696129.html.

A number of equities research analysts have recently issued reports on PRXL shares. Zacks Investment Research raised shares of PAREXEL International from a “hold” rating to a “buy” rating and set a $98.00 target price for the company in a research report on Tuesday, August 8th. BidaskClub cut shares of PAREXEL International from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $76.81.

PAREXEL International Co. (PRXL) traded down $0.02 on Friday, reaching $88.08. 7,021,100 shares of the company traded hands, compared to its average volume of 1,041,144. PAREXEL International Co. has a 1-year low of $51.16 and a 1-year high of $88.10. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.45 and a quick ratio of 1.45.

PAREXEL International (NASDAQ:PRXL) last posted its quarterly earnings data on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.94 by $0.08. PAREXEL International had a net margin of 4.62% and a return on equity of 19.95%. The business had revenue of $557.20 million during the quarter, compared to analysts’ expectations of $537.59 million. During the same quarter in the prior year, the business posted $0.94 earnings per share.

About PAREXEL International

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.